Safety Profile
Known Safety Concerns
- Copper depletion with prolonged high-dose use
- UL: 40 mg elemental zinc per day
- Nausea if taken without food
- Do not stack multiple zinc forms simultaneously
Contraindications
- Copper depletion with prolonged high-dose use
- UL: 40 mg elemental zinc per day
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Zinc picolinate is a chelated zinc form with good bioavailability. Contains approximately 20% elemental zinc. Often marketed as the most bioavailable zinc form, though evidence comparing it to gluconate and bisglycinate is mixed. Same safety profile as other organic zinc forms — copper depletion is the primary concern with prolonged high-dose use.
Biological and Chemical Classification
- Scientific Name
- Zinc picolinate
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 7 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Mineral
- Evidence consistency: High consistency across studies (100%)
- Copper depletion with prolonged high-dose use
- UL: 40 mg elemental zinc per day
- Nausea if taken without food
- Do not stack multiple zinc forms simultaneously
The available scientific evidence for Zinc Picolinate indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 7/40 |
| Evidence consistency | 20/20 |
| Safety signals | 6/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 7 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 7 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 24 მარ 2026, 11:03
Evidence Distribution
-
Observational / other LOW evidence YELLOWInfluence of Diet on the Bioaccessibility of Zn from Dietary Supplements: Findings from an In Vitro Digestion Model and Analytical Determinations. ↗Tokarczyk J et al.. Influence of Diet on the Bioaccessibility of Zn from Dietary Supplements: Findings from an In Vitro Digestion Model and Analytical Determinations.. Nutrients. 2025. PMID:41515211.PMID 41515211 ↗Journal NutrientsYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41515211/
-
Observational / other LOW evidence YELLOWZinc Picolinate Mitigates Colonic Inflammation and Enhances Barrier Function in a Rat Model of Ulcerative Colitis. ↗Han G et al.. Zinc Picolinate Mitigates Colonic Inflammation and Enhances Barrier Function in a Rat Model of Ulcerative Colitis.. Biol Trace Elem Res. 2025. PMID:41014484.PMID 41014484 ↗Journal Biol Trace Elem ResYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41014484/
-
Observational / other LOW evidence YELLOWEffects of magnesium picolinate, zinc picolinate, and selenomethionine co-supplementation on reproductive hormones, and glucose and lipid metabolism-related protein expressions in male rats… ↗Sahin K et al.. Effects of magnesium picolinate, zinc picolinate, and selenomethionine co-supplementation on reproductive hormones, and glucose and lipid metabolism-related protein expressions in male rats fed a high-fat diet.. Food Chem (Oxf). 2022. PMID:35415682.PMID 35415682 ↗Journal Food Chem (Oxf)Year 2022Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/35415682/
-
Observational / other LOW evidence YELLOWInhibition of Respiratory RNA Viruses by a Composition of Ionophoric Polyphenols with Metal Ions. ↗Kreiser T et al.. Inhibition of Respiratory RNA Viruses by a Composition of Ionophoric Polyphenols with Metal Ions.. Pharmaceuticals (Basel). 2022. PMID:35337174.PMID 35337174 ↗Journal Pharmaceuticals (Basel)Year 2022Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/35337174/
-
Observational / other LOW evidence YELLOWFeeding Zinc-Biofortified Wheat Improves Performance, Nutrient Digestibility, and Concentrations of Blood and Tissue Minerals in Quails. ↗Sahin N et al.. Feeding Zinc-Biofortified Wheat Improves Performance, Nutrient Digestibility, and Concentrations of Blood and Tissue Minerals in Quails.. Biol Trace Elem Res. 2022. PMID:34637103.PMID 34637103 ↗Journal Biol Trace Elem ResYear 2022Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/34637103/
-
Observational / other LOW evidence YELLOWA Case-Control Study for the Effectiveness of Oral Zinc in the Prevention and Mitigation of COVID-19. ↗Gordon AM et al.. A Case-Control Study for the Effectiveness of Oral Zinc in the Prevention and Mitigation of COVID-19.. Front Med (Lausanne). 2021. PMID:34966750.PMID 34966750 ↗Journal Front Med (Lausanne)Year 2021Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/34966750/
-
Observational / other LOW evidence YELLOWNutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial. ↗Sarris J et al.. Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial.. J Affect Disord. 2019. PMID:30699842.PMID 30699842 ↗Journal J Affect DisordYear 2019Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/30699842/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Zinc Picolinate. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Zinc Picolinate
A score of 3.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.